Neil Kay

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, S C, Department of Medicine, Division of Hematology Oncology at Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Med Insights Oncol 5:45-53. 2011
  2. pmc Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
  3. ncbi request reprint N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 50:588-92. 2009
  4. ncbi request reprint Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection
    N E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 19:531-2. 2005
  5. ncbi request reprint A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:1009-18. 2005
  6. ncbi request reprint Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia
    Neil E Kay
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Semin Hematol 43:S50-4. 2006
  7. ncbi request reprint The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
    N E Kay
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:1885-91. 2007
  8. ncbi request reprint IL-4 biology: impact on normal and leukemic CLL B cells
    Neil E Kay
    Division of Hematology, Department of Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Leuk Lymphoma 44:897-903. 2003
  9. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
  10. pmc Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
    Neil E Kay
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2180-7. 2010

Collaborators

Detail Information

Publications80

  1. pmc The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, S C, Department of Medicine, Division of Hematology Oncology at Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Med Insights Oncol 5:45-53. 2011
    ..We review studies that led to ofatumumab's approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent...
  2. pmc Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
    ..The extent of enhanced bone marrow angiogenesis in chronic lymphocytic leukemia (CLL) and relationship to proangiogenic factors and prognostic indicators is largely unexplored...
  3. ncbi request reprint N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 50:588-92. 2009
    ....
  4. ncbi request reprint Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection
    N E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 19:531-2. 2005
  5. ncbi request reprint A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:1009-18. 2005
    ..These studies suggest that the IL-4R, on B-CLL cells, can serve as a unique molecular target for directing cytotoxic agents in the therapy of B-CLL...
  6. ncbi request reprint Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia
    Neil E Kay
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Semin Hematol 43:S50-4. 2006
    ..Both fludarabine and pentostatin have shown improved responses when combined with alkylating agents and even higher overall and complete responses (CRs) when combined with monoclonal antibodies...
  7. ncbi request reprint The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
    N E Kay
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:1885-91. 2007
    ....
  8. ncbi request reprint IL-4 biology: impact on normal and leukemic CLL B cells
    Neil E Kay
    Division of Hematology, Department of Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Leuk Lymphoma 44:897-903. 2003
    ..Based on the increasing knowledge regarding the IL-4 pathway unique opportunities for therapy are now available in B-CLL...
  9. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  10. pmc Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
    Neil E Kay
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2180-7. 2010
    ..The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL)...
  11. doi request reprint Prognostic factors in chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 6 28, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 2:49-55. 2007
    ....
  12. ncbi request reprint Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis
    N E Kay
    Mayo Clinic, 200 First Street SW, Rochester, NY 55905, USA
    Br J Haematol 112:760-7. 2001
    ..These findings show that IL-4 is present in the microenvironment of B-CLL. In addition, use of agents that can interfere with IL-4 presentation to clonal B cells can be effective in increasing clonal B-cell apoptosis...
  13. pmc Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch"
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:899-906. 2007
    ..These results indicate the interaction between CLL B-cells and marrow stromal elements regulates angiogenic switching and may be linked to disease progression...
  14. ncbi request reprint Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients
    N E Kay
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:23-8. 2001
    ..Therapeutic efforts to maintain an intact immune system may be crucial in maximizing chemotherapeutic and/or immunotherapy efforts in this disease...
  15. pmc Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy
    Neil E Kay
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 203:161-8. 2010
    ..1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses...
  16. ncbi request reprint T-cell abnormalities in patients with chronic lymphocytic leukemia
    Tait Shanafelt
    Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1197-8. 2006
  17. ncbi request reprint Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
    P R Greipp
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 35:83-9. 1999
    ..Hypodiploid DNA content of plasma cells by flow cytometry may not be as ominous a factor as previously reported...
  18. ncbi request reprint Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies
    T D Shanafelt
    Mayo Clinic College of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:707-12. 2006
    ..An NCI sponsored phase I/II trial of de-caffeinated green tea extracts for patients with asymptomatic, early stage CLL opened at Mayo Clinic in August 2005...
  19. ncbi request reprint Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia
    D F Jelinek
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Br J Haematol 115:854-61. 2001
    ..These data strongly encourage the study of these biological markers as they relate to disease heterogeneity in B-CLL...
  20. doi request reprint Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
    Tait Shanafelt
    Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Leuk Lymphoma 51:2222-9. 2010
    ..No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL...
  21. ncbi request reprint CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation
    B T Pittner
    Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
    Leukemia 19:2264-72. 2005
    ..Taken together, these data suggest that CD38 is a marker of a more recently activated CLL B cell. This in turn may explain the biological and clinical differences between CD38-positive type B-CLL and CD38-negative type B-CLL...
  22. ncbi request reprint Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia
    G S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 130:36-42. 2005
    ..The IGH partner gene was not identified in two patients. We conclude that use of an IGH probe in FISH analysis of monoclonal B-cell lymphocytosis improves diagnostic precision and could have prognostic value in patients with CLL...
  23. ncbi request reprint B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
    N E Kay
    Department of Medicine, Division of Hematology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 16:911-9. 2002
    ....
  24. ncbi request reprint ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype
    J C Nolz
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
    Leukemia 19:1018-24. 2005
    ..These results provide new insight into normal human B-cell biology as well as provide clues about the transformed cell in B-CLL...
  25. ncbi request reprint VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance
    Y K Lee
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 19:513-23. 2005
    ..Thus, a VEGF-VEGF receptor pathway in CLL B cells can be linked to activation of STAT proteins that are able to enhance their apoptotic resistance...
  26. ncbi request reprint Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
    R Fonseca
    Mayo Clinic Department of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Minneapolis, MN, USA
    Leukemia 15:981-6. 2001
    ..Deletions involving 13q14 are very common in MM as detected by cIg-FISH. These deletions appear to predominantly involve loss of large segments of the 13q arm or monosomy 13, and only occasionally represent an interstitial deletion...
  27. ncbi request reprint Reconstitution of innate immunity in B-chronic lymphocytic leukemia: time to reconsider the possibilities
    Y K Lee
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leukemia 17:1945-7. 2003
  28. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  29. ncbi request reprint Combination therapies for previously untreated CLL
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 370:197-8. 2007
  30. pmc Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
    Laura Z Rassenti
    The Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
    Blood 112:1923-30. 2008
    ....
  31. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
    Tait D Shanafelt
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:2291-8. 2007
    ..Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients >or=70 years of age...
  32. ncbi request reprint Chronic lymphocytic leukemia: biology and current treatment
    Clive S Zent
    Division of Hematology, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 9:345-52. 2007
    ..These accomplishments have been accompanied by progressive improvement in the management of CLL and its complications. This review summarizes these changes and provides guidelines for a comprehensive approach to patient care...
  33. ncbi request reprint Angiogenesis revisited in CLL
    Neil E Kay
    Leuk Res 31:1459-60. 2007
  34. ncbi request reprint Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test
    Grzegorz S Nowakowski
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:449-53. 2007
    ..001). The percentage of smudge cells as a continuous variable correlated with overall survival (P=.04). The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL...
  35. pmc Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 113:2110-8. 2008
    ..In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab...
  36. ncbi request reprint Susceptibility genes and B-chronic lymphocytic leukaemia
    Susan L Slager
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 139:762-71. 2007
    ..The challenge of future studies of this type will be overcoming study design issues, including definition of CLL, sample size limitations and multiple testing issues...
  37. doi request reprint Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
    Tait D Shanafelt
    J Clin Oncol 26:e5-6. 2008
  38. pmc Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients
    Renee C Tschumper
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 118:306-15. 2008
    ..In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL...
  39. pmc MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
    Tait D Shanafelt
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:1458-61. 2008
    ..In contrast, CD38 predicted TTT (p=0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold...
  40. pmc The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:615-21. 2008
    ..Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients...
  41. ncbi request reprint Community-based phase II trial of PCR for CLL/SLL patients
    Neil E Kay
    Cancer Biother Radiopharm 22:713-4; author reply 715-7. 2007
  42. doi request reprint Controversies in the front-line management of chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, S C, Lutheran General Hospital, Department of Medicine, Division of Hematology and Medical Oncology, Park Ridge, IL 60068, USA
    Leuk Res 32:679-88. 2008
    ..The review is intended to discuss and simplify first-line therapy selection for patients with CLL in the era of new prognostic indicators and the better understanding of disease biology...
  43. ncbi request reprint Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 139:255-64. 2007
    ..The effects of CLL on QOL appear to differ from that of other malignancies with a more marked impact on emotional QOL. Research identifying efficacious psycho-oncologic support interventions for patients with CLL is needed...
  44. doi request reprint CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 140:537-46. 2008
    ..Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases. Clinical testing of anti-CD49d therapy in CLL appears warranted...
  45. pmc Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    Shanique Palmer
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 141:607-14. 2008
    ..These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted...
  46. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
    ....
  47. ncbi request reprint Chronic lymphocytic leukemia: current and emerging treatment approaches
    Neil E Kay
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Novel agents with unique, nonoverlapping mechanisms of action (eg, oblimersen sodium, lenalidomide, HuMax-CD20, GX15-070), and other treatments are under investigation in an attempt to further improve outcomes...
  48. ncbi request reprint Update on risk-stratified management for chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1738-46. 2006
    ..The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research...
  49. pmc Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents
    David R Barnidge
    Mayo Proteomics Research Center, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Proteome Res 4:1310-7. 2005
    ..These results demonstrate that stable isotope labeling and mass spectrometry can complement 2D gel electrophoresis and gene microarray technologies for identifying putative and perhaps unique prognostic markers in CLL...
  50. ncbi request reprint Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS
    David R Barnidge
    Mayo Proteomics Research Center, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 819:33-9. 2005
    ..We show that despite the variance in SCX, capillary LC, and the data-dependent selection of precursor ions, an overlap of 64% between proteins identified in replicate runs was achieved for this system...
  51. ncbi request reprint Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia
    Stephanie R Fink
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:253-62. 2005
    ..Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21...
  52. ncbi request reprint Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
    Joya Chandra
    Division of Oncology Research, Guggenheim 1301, Mayo Clinic, 200 First St, SW, Rochester, MN 55901, USA
    Blood 102:4512-9. 2003
    ....
  53. ncbi request reprint Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine
    Tait D Shanafelt
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Blood 105:2099-106. 2005
    ..Further preclinical development of adaphostin as a novel agent for the treatment of CLL appears warranted...
  54. ncbi request reprint ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
    Laura Z Rassenti
    Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego, La Jolla 92093, USA
    N Engl J Med 351:893-901. 2004
    ....
  55. ncbi request reprint Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 6:348-54. 2004
    ....
  56. ncbi request reprint The angiogenic status of B-CLL B cells: role of the VEGF receptors
    Neil E Kay
    Leuk Res 28:221-2. 2004
  57. ncbi request reprint Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488
    Martin M Oken
    Hubert H Humphrey Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Leuk Lymphoma 45:79-84. 2004
    ..However, these combination chemotherapies will need to be combined with appropriate addition of anti-bacterial and anti-viral prophylaxis to reduce infection risk for B-CLL patients...
  58. ncbi request reprint Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:318-25. 2004
    ..To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic leukemia (B-CLL)...
  59. ncbi request reprint Update on monoclonal antibody therapy in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Adv Hematol Oncol 2:107-13. 2004
    ..This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics...
  60. ncbi request reprint Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 121:287-95. 2003
    ..Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables...
  61. ncbi request reprint Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
    J Clin Oncol 24:4634-41. 2006
    ..There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH...
  62. ncbi request reprint Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study
    Rafael Fonseca
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:715-20. 2002
    ..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features...
  63. ncbi request reprint Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Rafael Fonseca
    Mayo Clinic Department of Hematology and Internal Medicine, Minneapolis, MN 55905, USA
    Blood 99:3735-41. 2002
    ..These patients do not have a worsened prognosis as previously thought...
  64. ncbi request reprint Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Am J Epidemiol 156:527-35. 2002
    ..The opposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance finding but, if confirmed, would suggest different etiologies for these malignancies...
  65. pmc Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
    Andrei V Ougolkov
    Division of Oncology Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 110:735-42. 2007
    ....
  66. ncbi request reprint Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival
    Anne J Novak
    Departments of Immunology, Pediatric and Adolescent Medicine, and Internal Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:2973-9. 2002
    ..Because these molecules are key regulators of B-cell homeostasis and tumor progression, leukemic cell autocrine expression of BLyS and APRIL may be playing an important role in the pathogenesis of this disease...
  67. ncbi request reprint Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia
    Kimberly J Stockero
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 166:152-6. 2006
    ..As a result of this study, we report evidence that B-CLL metaphases with 13q- are not detected because these deletions are often cryptic and not visible by standard G-banding...
  68. ncbi request reprint The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia
    Tait D Shanafelt
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Semin Oncol 33:174-85. 2006
    ....
  69. ncbi request reprint Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
    Robert A Kyle
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1958-66. 2006
    ..The importance of obtaining a complete response (CR) in multiple myeloma (MM) treated with chemotherapy is unclear...
  70. ncbi request reprint Identification of a global gene expression signature of B-chronic lymphocytic leukemia
    Diane F Jelinek
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Res 1:346-61. 2003
    ..Finally, we identified a group of 31 genes that distinguish between low (Rai stage 0) and high (Rai stage 4) risk patients, suggesting that there may also be a gene expression signature that associates with disease progression...
  71. ncbi request reprint VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
    Yean K Lee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:788-94. 2004
    ..Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death...
  72. pmc Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection
    Emanuela M Ghia
    Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
    Blood 111:5101-8. 2008
    ....
  73. ncbi request reprint Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
    Deborah A Bowen
    Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Leuk Lymphoma 48:2412-7. 2007
    ..Three-year survival was 41% (95% CI: 26 - 66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted...
  74. ncbi request reprint Highlights from the 46 th annual meeting of the American Society of Hematology
    Athanasios Fassas
    Clin Adv Hematol Oncol 3:111-6. 2005
  75. ncbi request reprint Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
    ..Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease...
  76. ncbi request reprint Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia
    Stephanie R Fink
    Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 167:177-81. 2006
    ..Translocations or isochromosome formations at sites of low-copy DNA repeats in 17p10 to 17p12 appear to be the mechanism for the loss of TP53 in B-CLL...
  77. ncbi request reprint Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia
    Tait D Shanafelt
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Ann Intern Med 145:435-47. 2006
    ..Recommendations for patient counseling, follow-up, supportive care, and initial treatment are presented for each risk category...
  78. ncbi request reprint Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia
    Tait D Shanafelt
    J Clin Oncol 24:3218-9; author reply 3219-20. 2006
  79. ncbi request reprint Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
    Chunrong Yu
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Ther 5:2378-87. 2006
    ..Further clinical development of this combination seems warranted...
  80. ncbi request reprint Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia
    Kami Maddocks-Christianson
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 139:398-404. 2007
    ..Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials...

Research Grants21

  1. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil E Kay; Fiscal Year: 2010
    ....
  2. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2002
    ..abstract_text> ..
  3. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil Kay; Fiscal Year: 2009
    ....
  4. VEGF Function in B-CLL
    Neil Kay; Fiscal Year: 2009
    ..3) Does the VEGF/VEGF-R pathway(s) found in CLL B cells correlate with either clinical and/or critical biologic parameters in B-CLL? ..
  5. Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia
    Neil Kay; Fiscal Year: 2009
    ....
  6. Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia
    Neil E Kay; Fiscal Year: 2010
    ....
  7. VEGF Function in B-CLL
    Neil Kay; Fiscal Year: 2007
    ..3) Does the VEGF/VEGF-R pathway(s) found in CLL B cells correlate with either clinical and/or critical biologic parameters in B-CLL? ..
  8. Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia
    Neil Kay; Fiscal Year: 2007
    ....
  9. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2006
    ..abstract_text> ..
  10. Angiogenesis in B Chronic Lymphocytic Leukemia
    Neil Kay; Fiscal Year: 2002
    ..This latter finding would strongly suggest that maneuvers to alter the angiogenic potential in B-CLL patients would be an important and novel therapeutic approach in this disease. ..
  11. B CLL Subtypes--Correlation with Clinical Outcome
    Neil Kay; Fiscal Year: 2002
    ....
  12. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2003
    ..abstract_text> ..
  13. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2004
    ..abstract_text> ..
  14. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2004
    ..abstract_text> ..
  15. B-CLL Biology: Impact of Combination Therapy
    Neil Kay; Fiscal Year: 2005
    ..abstract_text> ..
  16. Impact of Chemo-Immunotherapy in Relapsed/Refactory B-CLL
    Neil Kay; Fiscal Year: 2006
    ....
  17. VEGF Function in B-CLL
    Neil Kay; Fiscal Year: 2006
    ..3) Does the VEGF/VEGF-R pathway(s) found in CLL B cells correlate with either clinical and/or critical biologic parameters in B-CLL? ..
  18. VEGF Function in B-CLL
    Neil E Kay; Fiscal Year: 2010
    ..3) Does the VEGF/VEGF-R pathway(s) found in CLL B cells correlate with either clinical and/or critical biologic parameters in B-CLL? ..